Applying ADAURA in Practice: Implications for Early Stage EGFRm NSCLC - Medical Moment Two

Medical Moment Two: Expert Insight on Applying the ADAURA Results to Treatment of Early-Stage NSCLC Patients

 

This educational initiative is targeted to medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists and molecular pathologists who are involved in diagnosis of early stage NSCLC that is surgically resectable with curative intent. In addition to examining the latest ADAURA trial data and the potential utility of adjuvant osimertinib in stage IB-IIIA EGFRm NSCLC, the practice-changing implications of these results will also be explored from a variety of perspectives with three different specialties. There will be interactive discussion regarding practical strategies to ensure early biomarker testing to such that patients with EGFR-mutant disease can potentially benefit from adjuvant targeted therapies.


Supported by an independent educational grant from AstraZeneca.

Target Audience

This activity is designed to meet the educational needs of Medical Oncologists, Thoracic Surgeons, Molecular Pathologists, Radiation Oncologists, and Pulmonologists.

Learning Objectives

  • Evaluate practical strategies to ensure NSCLC patients are being diagnosed and receiving biomarker testing at earlier stages of disease, allowing those with resectable EGFRm NSCLC to benefit from adjuvant therapy, if indicated.
  • Examine the latest clinical data for the use of adjuvant osimertinib in early stage EGFRm NSCLC based on results from the ADAURA trial.
  • Discuss important clinical questions regarding the ADAURA trial and implications of study results in stage IB-IIIA EGFRm NSCLC from various clinical specialty perspectives.

Additional Information

AttachmentSize
ADAURA Handout and References680.47 KB
Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
Course opens: 
03/30/2021
Course expires: 
04/01/2022
Rating: 
0

Example Questions for Discussion:

  • What are the variety of systems that could be put in place to ensure molecular testing happens routinely for early-stage NSCLC?
  • How should communication flow between surgeons, pathologists and medical oncologists for patients with early stage NSCLC?
  • How do we weigh the importance of various outcomes when considering adjuvant therapies? 
  • How do we balance the potential value of therapy vs. cost of therapy?
  • What is the best evidence today regarding the roles of adjuvant radiation and adjuvant chemotherapy in a resected stage III EGFRm cancer? 
  • What should be done if there is recurrence after adjuvant osimertinib? How might you approach differently if local or metastatic recurrence?
  • What is the role of cfDNA in monitoring for residual disease?
  • What are the roles of the various members of the team (eg, molecular pathologist, medical oncologist, radiation oncologist, pulmonologist, etc.)?
     

Lecia V. Sequist, MD, MPH (Moderator)
Harvard Medical School
Massachusetts General Hospital
Boston, Massachusetts

 

Dr. Sequist is originally from Michigan and studied Chemistry at Cornell University. She received her MD from Harvard Medical School and trained in Internal Medicine at Brigham and Women’s Hospital and in Hematology/Oncology at the Dana-Farber Cancer Institute, where she also received an MPH from the Harvard School of Public Health.

Dr. Sequist joined the faculty at the Massachusetts General Hospital Cancer Center in 2005 and has an active clinical and translational research career, as well as a busy practice caring for patients with lung cancer. She is currently the Landry Family Professor of Medicine at Harvard Medical School and the Director of the Center for Innovation in Early Cancer Detection at Massachusetts General Hospital. She has held grants from the NIH, the DOD, and many private foundations. Dr. Sequist’s research focuses on studying targeted therapeutics for lung cancer and novel technologies to detect cancer earlier. In her free time, she likes to spend time with her husband, two sons and her dog, read, and travel.

 

Charu Aggarwal, MD, MPH
Leslye M. Heisler Associate Professor for Lung Cancer Excellence
University of Pennsylvania Abramson Cancer Center
Philadelphia, Pennsylvania



Dr. Aggarwal is the Leslye Heisler Associate Professor of Medicine in the Hematology-Oncology Division at the University of Pennsylvania’s Perelman School of Medicine. She is an active member of the Abramson Cancer Center (ACC) where she serves as Physician Leader for the clinical research program for Airways Malignancies.

Dr. Aggarwal specializes in the management of patients with lung cancer, with a specific and clinical research focus on the development of novel immunotherapeutic approaches, and the discovery and application of biomarkers to guide therapy and monitor treatment. She serves as the local and national principle investigator for multiple clinical trials focusing on the development of “targeted” immunotherapeutic approaches including cellular therapy and CAR-T for solid tumors. Dr. Aggarwal has led trials evaluating the role of plasma-based next generation sequencing in the management of patients with metastatic lung cancer.

She has extensive experience in the planning, design and execution of clinical trials, is an active member of ECOG, and has served as a national sub-study chair for SWOG-NCI’s LUNG-MAP. She has served on the Annual Meeting Scientific Program Committee of American Society of Clinical Oncology (ASCO), ASCO Education Committee and is a selected participant of the ASCO Leadership Development Program’s class of 2020. Dr. Aggarwal’s ultimate goal as a clinical and translational investigator is to perform patient-centered, scientifically relevant novel immunotherapy clinical trials that will make a tangible impact and advance our understanding of immunotherapy in patients with Lung Cancer.

 

Dara Aisner, MD, PhD
Associate Professor, Department of Pathology
University of Colorado Hospital
School of Medicine
Aurora, Colorado

 

Dr. Dara Aisner is a board-certified certified Anatomic and Molecular Genetic Pathologist. She is an Associate Professor of Pathology at the University of Colorado School of Medicine in Denver, Colorado and a member of the University of Colorado Comprehensive Cancer Center. She also recently became board certified in Clinical Informatics.

She is the Director of the Colorado Molecular Correlates Laboratory within the Department of Pathology. The laboratory provides CLIA level clinical services in the evaluation of patient tumor specimens for personalized medicine approaches.

She is a member of numerous oncology pathology and guidelines committees including the CAP/AMP/IASLC Guidelines for Biomarker Testing in Non-Small Cell Lung Cancer, among others. She is a member of the Association for Molecular Pathology, and is a member of the Economic Affairs Committee. She is also a member of the United States and Canadian Academy of Pathology, among other professional societies. Dr. Aisner is a leader among her academic peers in helping establish formal processes helping medical oncologists and pathologists work optimally together, which is especially important in today’s world of companion diagnostics, personalized medicine and Next-generation sequencing testing.

Dr. Aisner is the author of numerous publications and book chapters.

 

David Tom Cooke, MD, FACS
Associate Professor of Surgery
Chief, Division of General Thoracic Surgery
Vice Chair for Faculty Development & Wellness
UC Davis Health
Sacramento, California


Dr. David Tom Cooke is an Associate Professor at the University of California, Davis School of Medicine. He is the Chief of General Thoracic Surgery, Associate Director of Cardiothoracic Robotic Surgery, and the Vice Chair for Faculty Development and Wellness for the Department of Surgery. Dr. Cooke specializes in the surgical treatment of malignant and benign lung and esophageal disease and is a national leader in robotic thoracic surgery. Dr. Cooke's research includes oncologic trials, surgical outcomes/health services research, patient-centered outcomes research, surgical education, medical social media and public medical communication. He has authored over 100 scholarly works and co-authored a book. Dr. Cooke is recognized by Castle and Connolly and Sacramento Magazine as one of America's Top Doctors.

Dr. Cooke currently serves on the American Lung Association National Lung Cancer Expert Medical Advisory Panel. He is the co-founder of LCSMChat, the bi-monthly lung cancer, patient-centered social media Twitter chat and patient engagement network. Since its inception in 2013, the #LCSM community has had over 50,000 participants, 600,000 tweets and 2 billion impressions. Dr. Cooke completed his cardiothoracic surgery training at the University of Michigan in Ann Arbor, general surgery residency at the Massachusetts General Hospital, medical school at Harvard Medical School and undergraduate at UC Berkeley.


Planner and Faculty Disclosures

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners: 
Joan B. Fowler, PharmD—has no relevant financial relationships to disclose in relation to the content of this activity.
Lecia V. Sequist, MD, MPH—has disclosed that she is a consultant for AstraZeneca, Genentech, and Janssen and receives grant/research support from AstraZeneca, Boehringer Ingelheim, Genentech, and Novartis.

Authors/Presenters:
Lecia V. Sequist, MD, MPH—has disclosed that she is a consultant for AstraZeneca, Genentech, and Janssen and receives grant/research support from AstraZeneca, Boehringer Ingelheim, Genentech, and Novartis.
Charu Aggarwal, MD, MPH—has disclosed that she is a consultant for AstraZeneca, BMS, Celgene, Eli Lilly, Genentech, and Merck.
Dara Aisner, MD, PhD—has disclosed that she is a consultant for Blueprint Medicines and receives grant/research support from Genentech.
David Tom Cooke, MD, FACS—has no relevant financial relationships to disclose in relation to the content of this activity.

Peer Reviewer:
Vanessa Carranza, PharmD—has no relevant financial relationships to disclose in relation to the content of this activity.

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Medicine (ACCME)
CEC designates this live educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™ per webinar.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Upon completion of a CE Request Form, statements of credit for physicians will be issued.

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
Please login or register to take this course.